Molecular shifts in breast cancer following neoadjuvant chemotherapy: a prospective study and review of literature

Written by Singh AC; Pandey K; Agarwal S et al
Biomarkers Breast Journal articles Targeted therapies

This study, published in Future Oncology, investigated the changes in molecular subtype in breast cancer patients following neoadjuvant chemotherapy, finding significant alterations in ER, PR, HER-2 and Ki-67 levels. As such, the study emphasized the importance of tailored therapy and adjusting treatment strategies based on changes in tumor biomarkers. Access the full article Background Standard clinical guidelines recommend evaluating Estrogen & progesterone Receptor (ER, PR), Human epidermal growth factor receptor-2 (HER-2), and Ki-67 in breast cancer biopsy samples. This study investigates the changes in molecular subtype following neoadjuvant chemotherapy (NACT) in breast cancer patients. Methods Patients aged 18 to 65 years...

To view this content, please register now for access

It's completely free